ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - hepatitis a virus antigen, inactivated - תרחיף להזרקה - hepatitis a virus antigen, inactivated 1440 e.l.u/ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - active immunisation against infections caused by hepatitis a virus.the vaccine is particularly indicated for those at increased risk of infection or transmission.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - hepatitis a virus antigen, inactivated - תרחיף להזרקה - hepatitis a virus antigen, inactivated 720 e.l.u / 0.5 ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - havrix junior monodose vaccine is indicated for active immunisation against hav infection. the vaccine is particularly indicated for those at increased risk of infection or transmission.

ישראל - עברית - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - hepatitis a virus antigen, inactivated - תרחיף להזרקה - hepatitis a virus antigen, inactivated 25 units / 0.5 ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in children and adolescents 12 months of age and older .

ישראל - עברית - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - hepatitis a virus antigen, inactivated - תרחיף להזרקה - hepatitis a virus antigen, inactivated 50 u/ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 2 years of age and older.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - rabies, inactivated, whole virus - אבקה וממס להכנת תמיסה להזרקה - rabies, inactivated, whole virus 2.5 iu/ml - rabies, inactivated, whole virus - rabies, inactivated, whole virus - active immunization against rabies.

ישראל - עברית - Ministry of Health

sanofi israel ltd - rabies, inactivated, whole virus - אבקה וממס להכנת תרחיף להזרקה - rabies, inactivated, whole virus 2.5 iu - rabies, inactivated, whole virus - rabies, inactivated, whole virus - prevention of rabies in children and adults. it can be used before and after exposure, as a primary vaccination or as a booster dose.

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - encephalitis, tick borne, inactivated, whole virus - תרחיף להזרקה - encephalitis, tick borne, inactivated, whole virus 2.4 mcg / 0.5 ml - encephalitis, tick borne, inactivated, whole virus

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - encephalitis, tick borne, inactivated, whole virus - תרחיף להזרקה - encephalitis, tick borne, inactivated, whole virus 1.2 mcg / 0.25 ml - encephalitis, tick borne, inactivated, whole virus

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - diphtheria toxoid; fillamentous haemagglutinin (fha); haemophilus influenzae type b polysaccharide; inactivated polio virus (ipv) type 1; inactivated polio virus (ipv) type 2; inactivated polio virus (ipv) type 3; pertactin; pertussis toxoid (pt); tetanus toxoid - אבקה ותרחיף להכנת תרחיף להזרקה - diphtheria toxoid nlt 60 iu/ml; inactivated polio virus (ipv) type 3 64 du / 1 ml; inactivated polio virus (ipv) type 2 16 du / 1 ml; inactivated polio virus (ipv) type 1 80 du / 1 ml; pertussis toxoid (pt) 50 mcg/ml; fillamentous haemagglutinin (fha) 50 mcg/ml; pertactin 16 mcg/ml; tetanus toxoid nlt 80 iu/ml; haemophilus influenzae type b polysaccharide 20 mcg/vial - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus - diphtheria-hemophilus influenzae b-pertussis-poliomyelitis-tetanus - active immunisation in infants from the age of 2 months to 5 years against diptheria, tetanus, pertussis, poliomyelitis and haemophilus influenza type b. booster dose for children who have previously been immunised with dtp, polio and hib antigens

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - diphtheria toxoid; filamentous haemagglutinin (fha); inactivated polio virus (ipv) type 1; inactivated polio virus (ipv) type 2; inactivated polio virus (ipv) type 3; pertactin (prn or 69 kda omp); pertussis toxoid vaccine; tetanus toxoid - תרחיף להזרקה - pertactin (prn or 69 kda omp) 2.5 mcg / 0.5 ml; diphtheria toxoid nlt 2 iu / 0.5 ml; tetanus toxoid nlt 20 iu / 0.5 ml; filamentous haemagglutinin (fha) 8 mcg / 0.5 ml; pertussis toxoid vaccine 8 mcg / 0.5 ml; inactivated polio virus (ipv) type 3 32 du / 0.5 ml; inactivated polio virus (ipv) type 1 40 du / 0.5 ml; inactivated polio virus (ipv) type 2 8 du / 0.5 ml - bacterial and viral vaccines, combined - for booster vaccination against diphtheria, tetanus and pertusis and poliomyelitis of individuals from the age of four years onwards. boostrix polio is not intended for primary immunisation. the administration of boostrix polio should be based on official recommendations.